Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dissecting the role of toll-like receptor 7 in pancreatic cancer.
Stark M, Nicolai M, Tatura M, Keber CU, Kaufmann A, Chung HR, Slater EP, Heeschen C, Lawlor RT, Scarpa A, Bartsch DK, Gress TM, Bauer S, Buchholz M. Stark M, et al. Among authors: heeschen c. Cancer Med. 2023 Apr;12(7):8542-8556. doi: 10.1002/cam4.5606. Epub 2023 Jan 5. Cancer Med. 2023. PMID: 36602302 Free PMC article.
A Self-Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic Cancer.
Liu Y, Okesola BO, Osuna de la Peña D, Li W, Lin ML, Trabulo S, Tatari M, Lawlor RT, Scarpa A, Wang W, Knight M, Loessner D, Heeschen C, Mata A, Pearce OMT. Liu Y, et al. Among authors: heeschen c. Adv Healthc Mater. 2024 Mar 12:e2301941. doi: 10.1002/adhm.202301941. Online ahead of print. Adv Healthc Mater. 2024. PMID: 38471128
Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice.
Skeltved N, Nordmaj MA, Berendtsen NT, Dagil R, Stormer EMR, Al-Nakouzi N, Jiang K, Aicher A, Heeschen C, Gustavsson T, Choudhary S, Gögenur I, Christensen JP, Theander TG, Daugaard M, Salanti A, Nielsen MA. Skeltved N, et al. Among authors: heeschen c. J Exp Clin Cancer Res. 2023 Apr 28;42(1):106. doi: 10.1186/s13046-023-02655-8. J Exp Clin Cancer Res. 2023. PMID: 37118819 Free PMC article.
LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer.
Cave DD, Buonaiuto S, Sainz B Jr, Fantuz M, Mangini M, Carrer A, Di Domenico A, Iavazzo TT, Andolfi G, Cortina C, Sevillano M, Heeschen C, Colonna V, Corona M, Cucciardi A, Di Guida M, Batlle E, De Luca A, Lonardo E. Cave DD, et al. Among authors: heeschen c. J Exp Clin Cancer Res. 2022 Oct 26;41(1):315. doi: 10.1186/s13046-022-02516-w. J Exp Clin Cancer Res. 2022. PMID: 36289544 Free PMC article.
Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma.
Parejo-Alonso B, Royo-García A, Espiau-Romera P, Courtois S, Curiel-García Á, Zagorac S, Villaoslada I, Olive KP, Heeschen C, Sancho P. Parejo-Alonso B, et al. Among authors: heeschen c. Biomed Pharmacother. 2023 Feb;158:114162. doi: 10.1016/j.biopha.2022.114162. Epub 2022 Dec 24. Biomed Pharmacother. 2023. PMID: 36571997 Free article.
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. Liu NN, et al. Among authors: heeschen c. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21. Cancer Cell. 2023. PMID: 37738973
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. Liu NN, et al. Among authors: heeschen c. Cancer Cell. 2024 Feb 12;42(2):318-322. doi: 10.1016/j.ccell.2024.01.005. Cancer Cell. 2024. PMID: 38350423 No abstract available.
Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, Reina C, Chen M, Gu JM, He B, Alcala S, Behrens D, Lawlo RT, Scarpa A, Hidalgo M, Sainz B Jr, Sancho P, Heeschen C. Zheng Q, et al. Among authors: heeschen c. J Exp Clin Cancer Res. 2023 Nov 28;42(1):323. doi: 10.1186/s13046-023-02883-y. J Exp Clin Cancer Res. 2023. PMID: 38012687 Free PMC article.
153 results